Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Patent
1997-05-06
1999-12-14
Dees, Jose' G.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
424 111, 424 153, 424 91, 4241831, A61K 5100, A61M 3614
Patent
active
06001329&
ABSTRACT:
The present invention provides the synthesis and purification of a new class of compounds known as radiolabeled fusion toxins (RFT), in which both toxin and radionuclide tags are contained on the same growth factor, for example, murine granulocyte macrophage colony stimulating factor, mGM-CSF, epidermal growth factor, or murine interleukin-4, mIL-4.
REFERENCES:
patent: 4962188 (1990-10-01), Frankel
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5776427 (1998-07-01), Thorpe et al.
Blazar Bruce R.
Buchsbaum Donald J.
Vallera Daniel A.
Adler Benjamin Aaron
Dees Jos,e G.
Jones Dameron
UAB Research Foundation
LandOfFree
Radiolabeled fusion toxins for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabeled fusion toxins for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeled fusion toxins for cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-860327